fda approval for semaglutide Expands Use CV, Kidney Risks in T2D, CKD The #FDA approved the first

While some people experience rebound weight gain, research shows that more than half of patients maintain their weight loss even a year after discontinuing the medication

On average, patients using semaglutide GLP-1 achieve substantial weight loss ranging from 10 to 20% of their starting weight

Reducing this risk is a key part of our commitment to driving change for this community, as we work to increase manufacturing capacity to responsibly supply this important medicine. The FDA decision is based on the results of the landmark SELECT phase 3 cardiovascular outcomes trial that examined the effect of adding Wegovy 2.4mg or placebo to cardiovascular standard of care in adults with overweight and obesity with established cardiovascular disease and without diabetes

a subpotent dose can delay expected benefits and lead to unnecessary dose escalations, and an infection can result in urgent care visits

The 4.0 mL option deserves special attention if you prefer cleaner math

Advanced dosing strategies Once you understand the basics, several advanced approaches can optimize your protocol further